Related Experiment Video
Updated: Apr 12, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer
Tetje C van der Sluis1, Sjoerd H van der Burg2, Ramon Arens1
1Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), 2300 RC, The Netherlands.
Abstract:
The identification of human papillomavirus as the etiological factor for cervical cancer provides an opportunity to treat these malignancies by vaccination. Although therapeutic vaccination against viral oncogenes regularly induces a specific T cell response, clinical effectivity remains low. Three factors are particularly important for clinical outcome: the balance between cytotoxic T cells and regulatory immune subsets, the balance between cytotoxic T cells and tumor cells and finally the killing efficiency of cytotoxic T cells within the tumor. To improve these three factors, therapeutic vaccination is combined with other treatments. Here, we review those studies that are based on understanding the inhibitory mechanisms that prevent unleashing the full power of therapeutic vaccine-induced T cells and utilize combinatorial interventions based on these insights.
Insights
Therapeutic vaccines for human papillomavirus-induced cervical cancer show low effectiveness. Combining vaccines with other treatments may improve outcomes by enhancing T cell responses and overcoming tumor-induced suppression.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Human papillomavirus (HPV) is the primary cause of cervical cancer.
- Therapeutic vaccination against HPV oncogenes elicits T cell responses but has limited clinical success.
Purpose of the Study:
- To review studies investigating strategies to enhance the clinical efficacy of therapeutic cancer vaccines.
- To explore combinatorial treatments that address key factors limiting vaccine effectiveness.
Main Methods:
- Review of scientific literature focusing on therapeutic vaccination for HPV-related cancers.
- Analysis of studies examining immune responses, tumor microenvironment interactions, and T cell cytotoxicity.
Main Results:
- Clinical outcomes are influenced by the balance of cytotoxic and regulatory T cells, tumor cell burden, and T cell killing efficiency.
- Understanding immune inhibitory mechanisms is crucial for improving vaccine efficacy.
Conclusions:
- Combinatorial interventions targeting immune suppression and enhancing T cell function are essential for improving therapeutic vaccine effectiveness in cervical cancer.
- Further research into overcoming inhibitory mechanisms will optimize vaccine-based cancer therapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:51Vaccinations